Multiple Sclerosis

Avonex, frequently prescribed multiple sclerosis treatment, shows superior adherence

Published in Medical Letter on the CDC and FDA, October 29th, 2006

Biogen Idec (BIIB) announced findings from the Global Adherence Project (GAP) that demonstrated patients taking Avonex (interferon beta-1a), a widely prescribed multiple sclerosis (MS) treatment, adhered to treatment more than patients taking other approved disease-modifying therapies included in the study.

GAP is the largest study of its kind to evaluate patient adherence to long-term treatments for multiple sclerosis in a real-world setting with 176 sites across 22 countries participating. The cross-sectional observational study enrolled 2,566 patients with relapsing-remitting MS taking one of the DMTs.

Neurologists completed a practice-related...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2006-10-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry